Kessler Topaz Meltzer & Check, LLP: Investigation on Behalf of Emergent BioSolutions Inc. Shareholders
Emergent BioSolutions, Inc. (“Emergent BioSolutions”), provides specialty products that address accidental, deliberate, and naturally occurring public health threats. One of Emergent BioSolutions’ products, NARCAN nasal spray, is used as an emergency treatment for known or suspected opioid overdoses.
Kessler Topaz Meltzer & Check, LLP (“Kessler Topaz”) is investigating potential claims on behalf of purchasers of Emergent BioSolutions (NYSE: EBS) securities between April 30, 2020 through June 5, 2020. Kessler Topaz’s investigation concerns the possible issuance of false and/or misleading statements by Emergent BioSolutions and other violations of the federal securities laws in connection with the NARCAN nasal spray.
Emergent BioSolutions investors may receive additional information about the case by clicking the link “Submit Your Information” above and filling out the form as promptly as possible.
If you wish to discuss this action or have any questions concerning your rights or interests with respect to these matters, please contact Kessler Topaz toll free at 1-844-887-9500 or 1-610-667-7706, or via e-mail at [email protected].
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
1-844-887-9500 (toll free) or 1-610-667-7706
Or by e-mail at [email protected]
Please complete this form relating to your transactions for Emergent BioSolutions, Inc. (NYSE: EBS) securities between April 30, 2020 through June 5, 2020, both dates inclusive (the “Class Period”).
You may also contact James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; or toll free at (844) 887-9500; or you may submit your information via email at [email protected], or you may click here to print a PDF of this form.